Immunogenicity of the S protein of transmissible gastroenteritis virus expressed in baculovirus

Tuboly, Tamás; Nagy, Éva; Dennis, John R.; Derbyshire, J.B.

doi:10.1007/bf01311173

Cited by 21 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the major inducer of TGEV-neutralizing antibodies, the S protein has been used mainly for the induction of protective immunity to TGEV and four major antigenic sites (A, B, C and D) have been defined on the aminoterminal domain [4,5]. Earlier studies have shown that the intact globular N-terminal half of the S protein is sufficient to achieve a protective immune response equivalent to that induced by the full S protein [6].…”

Section: Introductionmentioning

confidence: 99%

Intragastric administration of attenuated Salmonella typhimurium harbouring transmissible gastroenteritis virus (TGEV) DNA vaccine induced specific antibody production

Heng

Cao

Huang

et al. 2009

Vaccine

View full text Add to dashboard Cite

Attenuated Salmonella typhimurium was selected as a transgenic vehicle for the development of live mucosal vaccines against transmissible gastroenteritis virus (TGEV). A 2.2kb DNA fragment, encoding for N-terminal domain glycoprotein S of TGEV, was amplified by RT-PCR and cloned into eukaryotic expression vector pVAX1. The recombinant plasmid pVAX-S was transformed by electroporation into attenuated S. typhimurium SL7207, the expression and translation of the pVAX-S delivered by recombinant S. typhimurium SL7207 (pVAX-S) was detected in vitro and in vivo respectively. BALB/c mice were inoculated orally with SL7207 (pVAX-S) at different dosages, the bacterium was safe to mice at dosage of 2x10(9)CFU and eventually eliminated from the spleen and liver at week 4 post-immunization. Mice immunized with different dosages of SL7207 (pVAX-S) elicited specific anti-TGEV local mucosal and humoral responses as measured by indirect ELISA assay. Moreover, the immunogenicity of the DNA vaccine was highly dependent on the dosage of the attenuated bacteria used for oral administration, 10(9)CFU dosage group showed higher antibody response than 10(8)CFU and 10(7)CFU dosages groups during week 4-8 post-immunization. The results indicated that attenuated S. typhimurium could be used as a delivery vector for oral immunization of TGEV DNA vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%

Intragastric administration of attenuated Salmonella typhimurium harbouring transmissible gastroenteritis virus (TGEV) DNA vaccine induced specific antibody production

Heng

Cao

Huang

et al. 2009

Vaccine

View full text Add to dashboard Cite

show abstract

“…Baculovirus-infected cells containing the N-terminal fragment of the S-antigen induced neutralizing serum antibodies in piglets (Tuboly et al 1994). Furthermore, oral immunization of piglets using S-antigen-recombinant porcine adenovirus induced both neutralizing antibodies in sera and mucosal antibodies in the intestine (Tuboly et al 2001).…”

Section: Review Of Past Efforts To Produce Tgev Vaccinesmentioning

confidence: 97%

An Oral Vaccine for TGEV Immunization of Pigs

Rajan

2014

Commercial Plant-Produced Recombinant Protein Products

View full text Add to dashboard Cite

“…Because the baculovirus expression system permits the production of high quantities of foreign proteins in secreted form and the preservation of the native conformation of glycoproteins, including posttranslational modifications such as N-glycosylation, this system represents an attractive method for production of diagnostic reagents. 20,27 The objectives of this study were to simplify blocking ELISA procedures by using recombinant baculovirus S protein antigen for coating and to evaluate its potential for large-scale testing. Comparison of the sera of TGEV-infected, PRCV-infected, and negative control animals revealed that at 21-28 PID blocking § Percentage of pigs that tested positive.…”

Section: Discussionmentioning

confidence: 99%

“…15 The spike (S) glycoprotein is 1 of the 4 structural TGEV/PRCV proteins, but only the S protein contains epitopes that induce virus-neutralizing antibodies. 27 The S glycoprotein contains 4 major antigenic sites (A, B, C, D), antibodies to which can be found in the serum of TGEV-infected pigs. The loss of antigenic epitope D on PRCV strains enables the differential di-agnosis of TGEV and PRCV by the use of monoclonal antibodies (MAbs) to epitope D.…”

mentioning

confidence: 99%

Evaluation of the Baculovirus-Expressed S Glycoprotein of Transmissible Gastroenteritis Virus (TGEV) as Antigen in a Competition ELISA to Differentiate Porcine Respiratory Coronavirus from TGEV Antibodies in Pigs

Sestak¹,

Zhou²,

Shoup³

et al. 1999

J VET Diagn Invest

View full text Add to dashboard Cite

Abstract. The spike (S) glycoprotein of the Miller strain of transmissible gastroenteritis virus (TGEV) was recently cloned and expressed in baculovirus. The recombinant S protein was used as the coating antigen in a competition (blocking) enzyme-linked immunosorbent assay (ELISA) in combination with monoclonal antibodies to the S protein epitope A (conserved on TGEV and porcine respiratory coronavirus [PRCV]) or epitope D (present on TGEV only) to differentiate PRCV-from TGEV-induced antibodies. One set (set A) of 125 serum samples were collected at different times after inoculation of caesarean-derived, colostrum-deprived (n ϭ 52) and conventional young pigs (n ϭ 73) with 1 of the 2 porcine coronaviruses or uninoculated negative controls (TGEV/PRCV/negative ϭ 75/30/20). A second set (set B) of 63 serum samples originated from adult sows inoculated with PRCV and the recombinant TGEV S protein or with mock-protein control and then exposed to virulent TGEV after challenge of their litters. Sera from set A were used to assess the accuracy indicators (sensitivity, specificity, accuracy) of the fixed-cell blocking ELISA, which uses swine testicular cells infected with the M6 strain of TGEV as the antigen source (ELISA 1) and the newly developed ELISA based on the recombinant S protein as antigen (ELISA 2). The sera from set B (adults) were tested for comparison. The plaque reduction virus neutralization test was used as a confirmatory test for the presence of antibodies to TGEV/PRCV in the test sera. The accuracy indicators for both ELISAs suggest that differential diagnosis can be of practical use at least 3 weeks after inoculation by testing the dual (acute/convalescent) samples from each individual in conjunction with another confirmatory (virus neutralization) antibody assay to provide valid and complete differentiation information. Moreover, whereas ELISA 1 had 10-20% false positive results to epitope D for PRCV-infected pigs (set A samples), no false-positive results to epitope D occurred using ELISA 2, indicating its greater specificity. The progression of seroresponses to the TGEV S protein epitopes A or D, as measured by the 2 ELISAs, was similar for both sets (A and B) of samples. Differentiation between TGEV and PRCV antibodies (based on seroresponses to epitope D) was consistently measured after the third week of inoculation.Transmissible gastroenteritis virus (TGEV), a prominent cause of neonatal diarrhea, causes death in 90-100% of seronegative pigs under 2 weeks of age and costs the US swine industry nearly $200 million/ year. 15,19 Surveys of TGEV antibodies in swine sera collected prior to the detection of porcine respiratory coronavirus (PRCV) indicated that 19-54% of swine herds in North America have antibodies, 17 but few differential serosurveys have been done since the detection of PRCV. 32 A variant of TGEV, referred to as PRCV, was isolated from pigs in Europe in 1986 and identified in the USA in 1989. 15,18,19 As reported from Iowa swine herds, a recent increase observed in TGEV/PRCV seropre...

show abstract

Immunogenicity of the S protein of transmissible gastroenteritis virus expressed in baculovirus

Cited by 21 publications

References 27 publications

Intragastric administration of attenuated Salmonella typhimurium harbouring transmissible gastroenteritis virus (TGEV) DNA vaccine induced specific antibody production

Intragastric administration of attenuated Salmonella typhimurium harbouring transmissible gastroenteritis virus (TGEV) DNA vaccine induced specific antibody production

An Oral Vaccine for TGEV Immunization of Pigs

Evaluation of the Baculovirus-Expressed S Glycoprotein of Transmissible Gastroenteritis Virus (TGEV) as Antigen in a Competition ELISA to Differentiate Porcine Respiratory Coronavirus from TGEV Antibodies in Pigs

Contact Info

Product

Resources

About